For example, recent studies indicate that mismatch repair deficient tumours respond to immune checkpoint anti-programmed cell death 1 inhibitors in contrast to mismatch repair proficient tumours which showed no response [43]. This evidence concerns the gene PDCD1 and neoplasm.